WallStSmart

Merck & Company Inc (MRK)vsNovo Nordisk A/S (NVO)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novo Nordisk A/S generates 395% more annual revenue ($333.65B vs $67.38B). NVO leads profitability with a 33.9% profit margin vs 3.6%. MRK appears more attractively valued with a PEG of 3.56. NVO earns a higher WallStSmart Score of 59/100 (C).

MRK

Hold

42

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

NVO

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 10.0Value: 5.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$85.13

Current Price

$133.72

$48.59 premium

UndervaluedFair: $85.13Overvalued

Intrinsic value data unavailable for NVO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$362.27B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

NVO6 strengths · Avg: 9.8/10
P/E RatioValuation
10.2x10/10

Attractively priced relative to earnings

Return on EquityProfitability
52.0%10/10

Every $100 of equity generates 52 in profit

Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
40.1%10/10

Strong operational efficiency at 40.1%

Free Cash FlowQuality
$28.10B10/10

Generating 28.1B in free cash flow

Market CapQuality
$177.74B9/10

Large-cap with strong market position

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Debt/EquityHealth
1.203/10

Elevated debt levels

NVO3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.482/10

Expensive relative to growth rate

EPS GrowthGrowth
-15.8%2/10

Earnings declined 15.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NVO

The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.9% and operating margin at 40.1%.

Bear Case : MRK

The primary concerns for MRK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 148.4x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Bear Case : NVO

The primary concerns for NVO are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

MRK profiles as a value stock while NVO is a mature play — different risk/reward profiles.

NVO carries more volatility with a beta of 0.37 — expect wider price swings.

NVO is growing revenue faster at 5.6% — sustainability is the question.

NVO generates stronger free cash flow (28.1B), providing more financial flexibility.

Bottom Line

NVO scores higher overall (59/100 vs 42/100), backed by strong 33.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Novo Nordisk A/S

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

Want to dig deeper into these stocks?